Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Single-Arm Phase 2 Study to Evaluate AMEILE (Almonertinib, Previously also known as HS-10296) in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR T790M Mutations

Next Previous
Trial Profile

A Multicenter, Open-Label, Single-Arm Phase 2 Study to Evaluate AMEILE (Almonertinib, Previously also known as HS-10296) in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR T790M Mutations

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aumolertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Jiangsu Hansoh Pharmaceutical

Most Recent Events

  • 17 Sep 2021 According to EORx media release, final results from this study presented at ESMO 2021
  • 17 Sep 2021 Results published in the EQRx Media Release
  • 20 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top